Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

被引：0

作者：

Von Minckwitz, Gunter

Hahnen, Eric

Fasching, Peter A.

Hauke, Jan

Schneeweiss, Andreas

Salat, Christoph

Rezai, Mandi

Blohmer, Jens U.

Zahm, Dirk Michael

Jackisch, Christian

Gerber, Bernd

Klare, Peter

Kummel, Sherko

Eidtmann, Holger

Paepke, Stefan

Nekljudova, Valentina

Le Loibl, Sibyl

Untch, Michael

Schmutzler, Rita K.

机构：

[1] Goethe Univ Frankfurt, German Breast Grp, D-60054 Frankfurt, Germany

[2] Univ Cologne, D-50931 Cologne, Germany

[3] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany

[4] Univ Heidelberg Hosp, Heidelberg, Germany

[5] Hematol Oncol Clin, Munich, Germany

[6] Louisen Hosp, Breast Ctr Duesseldorf, Dusseldorf, Germany

[7] Brustzentrum Sankt Gertrauden Krankenhaus, Berlin, Germany

[8] Frauenklin Gera, Gera, Germany

[9] Sana Kliniken Offenbach, Offenbach, Germany

[10] Univ Rostock, D-18055 Rostock, Germany

[11] Praxisklin Krebsheilkunde, Berlin, Germany

[12] Evangel Huyssens Stiftung, Kliniken Essen Mitte, Breast Canc Ctr, Essen, Germany

[13] Univ Kiel, Kiel, Germany

[14] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-80290 Munich, Germany

[15] German Breast Grp, Neu Isenburg, Germany

[16] Sana Klinikurn Offenbach, German Breast Grp, Neu Isenburg, Germany

[17] Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany

[18] Helios Klinikum Berlin Buch, Multidisciplinary Breast Canc Ctr, Berlin, Germany

[19] Ctr Familial Breast & Ovarian Canc, Cologne, Germany

[20] Ctr Integrated Oncol, Cologne, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1005

引用

页数：1

共 50 条

[21] Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen, Eric
Lederer, Bianca
Hauke, Jan
Loibl, Sibylle
Kroeber, Sandra
Schneeweiss, Andreas
Denkert, Carsten
Fasching, Peter A.
Blohmer, Jens U.
Jackisch, Christian
Paepke, Stefan
Gerber, Bernd
Kuemmel, Sherko
Schem, Christian
Neidhardt, Guido
Huober, Jens
Rhiem, Kerstin
Costa, Serban
Altmueller, Janine
Hanusch, Claus
Thiele, Holger
Mueller, Volkmar
Nuernberg, Peter
Karn, Thomas
Nekljudova, Valentina
Untch, Michael
von Minckwitz, Gunter
Schmutzler, Rita K.
JAMA ONCOLOGY, 2017, 3 (10) : 1378 - 1385
[22] The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum-based neoadjuvant chemotherapy
Goldvaser, H.
Kuchuk, I.
Yerushalmi, R.
Goldshtein, A.
Rotem, O.
Lotan, A.
Gabizon, A. A.
Mutai, R.
ANNALS OF ONCOLOGY, 2023, 34 : S330 - S330
[23] Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C)
Chang, H. R.
Slamon, D.
Gornbein, J. A.
Chung, D.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[24] Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
Lejeune, Marylene
Reverte, Laia
Sauras, Esther
Gallardo, Noelia
Bosch, Ramon
Roso, Albert
Petit, Anna
Peg, Vicente
Riu, Francisco
Garcia-Fontgivell, Joan
Ibanez, Jose
Relea, Fernanda
Vieites, Begona
Bor, Catherine
de la Cruz-Merino, Luis
Arenas, Meritxell
Rodriguez, Valerie
Galera, Juana
Korzynska, Anna
Belhomme, Philippe
Plancoulaine, Benoit
alvaro, Tomas
Lopez, Carlos
CANCERS, 2023, 15 (03)
[25] Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Gass, Paul
Lux, Michael P.
Rauh, Claudia
Hein, Alexander
Bani, Mayada R.
Fiessler, Cornelia
Hartmann, Arndt
Haeberle, Lothar
Pretscher, Jutta
Erber, Ramona
Wachter, David L.
Schulz-Wendtland, Ruediger
Beckmann, Matthias W.
Fasching, Peter A.
Wunderle, Marius
BMC CANCER, 2018, 18
[26] Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Paul Gass
Michael P. Lux
Claudia Rauh
Alexander Hein
Mayada R. Bani
Cornelia Fiessler
Arndt Hartmann
Lothar Häberle
Jutta Pretscher
Ramona Erber
David L. Wachter
Rüdiger Schulz-Wendtland
Matthias W. Beckmann
Peter A. Fasching
Marius Wunderle
BMC Cancer, 18
[27] BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy
Mathilde Foedermayr
Miriam Sebesta
Margaretha Rudas
Anna S. Berghoff
Regina Promberger
Matthias Preusser
Peter Dubsky
Florian Fitzal
Michael Gnant
Guenther G. Steger
Ansgar Weltermann
Christoph C. Zielinski
Otto Zach
Rupert Bartsch
Cancer Chemotherapy and Pharmacology, 2014, 73 : 771 - 778
[28] BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy
Foedermayr, Mathilde
Sebesta, Miriam
Rudas, Margaretha
Berghoff, Anna S.
Promberger, Regina
Preusser, Matthias
Dubsky, Peter
Fitzal, Florian
Gnant, Michael
Steger, Guenther G.
Weltermann, Ansgar
Zielinski, Christoph C.
Zach, Otto
Bartsch, Rupert
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 771 - 778
[29] Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach
Kedzierawski, Piotr
Macek, Pawel
Ciepiela, Izabela
Kowalik, Artur
Gozdz, Stanislaw
DIAGNOSTICS, 2021, 11 (07)
[30] Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer
Masuda, Hiroko
Baggerly, Keith A.
Wang, Ying
Zhang, Ya
Gonzalez-Angulo, Ana M.
Meric-Bernstam, Funda
Valero, Vicente
Lehmann, Brian D.
Pietenpol, Jennifer A.
Hortobagyi, Gabriel N.
Symmans, William Fraser
Ueno, Naoto T.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →